<DOC>
	<DOCNO>NCT00472433</DOCNO>
	<brief_summary>The majority case autoimmune cytopenia , include immune thrombocytopenia ( ITP ) , autoimmune hemolytic anemia , autoimmune neutropenia ( AIN ) pure red cell aplasia , respond conventional immunosuppressive therapy without splenectomy . There , however , group patient refractory chronically relapse autoimmune cytopenia cause life-threatening hemorrhage , infection anemia . Further problem include short- long-term side-effects corticosteroid , potential toxicity immunosuppressive cytotoxic agent . An alternative le toxic approach patient may treatment Campath-1H , humanize IgG monoclonal antibody specific CD52 antigen present human lymphocytes monocyte . The main effect Campath-1H T cell result prolong profound depletion CD4 CD8 subpopulation , particularly CD4 population , might `` reset '' immune system without need total immune ablation.Therefore , study design investigate safety efficacy repeat Campath treatment cycle autoimmune cytopenia.In order minimize possible side effect accumulate Campath , 3 treatment cycle administer consecutively reduce dos .</brief_summary>
	<brief_title>The Efficacy Safety Alemtuzumab Auotoimmune Cytopenias</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Leukopenia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>1 . Patients must diagnosis follow autoimmune cytopenia : immune thromobocytopenia purpura ( ITP ) autoimmune hemolytic anemia ( AIHA ) autoimmune neutropenia ( AIN ) pure red cell aplasia ( PRCA ) 2 . Patients must refractory disease accord follow criterion 1. respond steroid 2. need prednisolone 15 mg/d maintenance therapy 3 . Complete work baseline evaluation measurement 4 . Age &gt; 18 year 5 . Patient 's free write inform consent 1 . Patients know hypersensitivity murine protein component alemtuzumab 2 . Patients poor performance status ( ECOG criterion 34 ) 3 . Serologic evidence human immunodeficiency virus exposure 4 . Patients active uncontrolled infection . Patients HIV positive test positive HBs HCV antigens . 5 . Pregnant lactate woman 6 . Serious medical psychiatric illness prevent inform consent 7 . Patients likely lose follow ( eg , unwilling difficult return , contact ) 8 . Patients active malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Alemtuzumab autoimmune cytopenia</keyword>
</DOC>